Fig. 3
The influence of 1-MNA and 1,4-DMP on tumor angiogenesis estimated in the matrigel plug assay. a Mean microvessel density (MVD) quantified in matrigel plug sections collected on the 7th day after their implantation and stained with anti-CD31 antibody. Data are presented as median values ± min/max. b Images of sections stained with anti-CD31 antibody for untreated animals (I), mice treated with cyclophosphamide (CP) at the dose of 25 mg/kg given intraperitoneally on days 0, 3 and 5 (II), mice treated with 1-MNA (III) and mice treated with 1,4-DMP (IV). Both 1-MNA and 1,4-DMP were given at the dose of 100 mg/kg/day in drinking water, starting from the day of matrigel plug implantation. Plasma levels of: c 6-keto-PGF1α, d TXB2, e soluble P-selectin, f vWF in mice treated with cyclophosphamide, 1-MNA or 1,4-DMP; all data are presented as median values ± min/max, dotted lines on the graphs correspond to the value of the median concentration determined for respective agents in healthy BALB/c mice